ReviewWorld journal of methodology2024

Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.

Subhodip Pramanik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.